Validation of PON1 enzyme activity assays for longitudinal studies

Clinica Chimica Acta

Volumn 402, Issue 1-2, 2009, Pages 67-74

  Huen, Karen ^a   Richter, Rebecca ^b   Furlong, Clement ^b   Eskenazi, Brenda ^a   Holland, Nina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Arylesterase; Birth cohort; Children; Enzymatic assay; Freeze thaw; Organophosphate; Oxidative stress; Paraoxonase; Pesticides; PON1 activity; Storage; Technical variability; Temperature

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE;

ADOLESCENT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SUBSTRATE COMPLEX; FREEZING; HUMAN; LONGITUDINAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STORAGE TEMPERATURE; THAWING; VALIDATION PROCESS;

ADOLESCENT; ARYLDIALKYLPHOSPHATASE; CHILD; CHILD, PRESCHOOL; CHLORPYRIFOS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; OBSERVER VARIATION; ORGANOPHOSPHORUS COMPOUNDS; PARAOXON; SPECTROPHOTOMETRY;

EID: 60649119123     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.12.019     Document Type: Article

References (41)

1. Li H.L., Liu D.P., and Liang C.C. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 81 (2003) 766-779
2. Costa L.G., Cole T.B., Vitalone A., and Furlong C.E. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 352 (2005) 37-47
3. DPR, Pesticide Use Report, Annual. Sacramento, CA: Department of Pesticide Regulation, California Environmental Protection Agency, 2005 (2005)
4. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
5. Aviram M., and Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 37 (2004) 1304-1316
6. Rosenblat M., Gaidukov L., Khersonsky O., et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 281 (2006) 7657-7665
7. Tward A., Xia Y.R., Wang X.P., et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106 (2002) 484-490
8. Eskenazi B., Bradman A., and Castorina R. Exposures of children to organophosphate pesticides and their potential adverse health effects. Environ Health Perspect 107 Suppl 3 (1999) 409-419
9. Eskenazi B., Harley K., Bradman A., et al. Association of in utero organophosphate pesticide exposure and fetal growth and length of gestation in an agricultural population. Environ Health Perspect 112 (2004) 1116-1124
10. Young J.G., Eskenazi B., Gladstone E.A., et al. Association between in utero organophosphate pesticide exposure and abnormal reflexes in neonates. Neurotoxicology 26 (2005) 199-209
11. Berkowitz G.S., Wetmur J.G., Birman-Deych E., et al. In utero pesticide exposure, maternal paraoxonase activity, and head circumference. Environ Health Perspect 112 (2004) 388-391
12. Chen J., Chan W., Wallenstein S., Berkowitz G., and Wetmur J.G. Haplotype-phenotype relationships of paraoxonase-1. Cancer Epidemiol Biomark Prev 14 (2005) 731-734
13. Lawlor D.A., Gaunt T.R., Hinks L.J., et al. The association of the PON1 Q192R polymorphism with complications and outcomes of pregnancy: findings from the British Women's Heart and Health cohort study. Paediatr Perinat Epidemiol 20 (2006) 244-250
14. Erlich P.M., Lunetta K.L., Cupples L.A., et al. Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum Mol Genet 15 (2006) 77-85
15. Zintzaras E., and Hadjigeorgiou G.M. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. J Hum Genet 49 (2004) 474-481
16. Bhattacharyya T., Nicholls S.J., Topol E.J., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. Jama 299 (2008) 1265-1276
17. Browne R.W., Koury S.T., Marion S., Wilding G., Muti P., and Trevisan M. Accuracy and biological variation of human serum paraoxonase 1 activity and polymorphism (Q192R) by kinetic enzyme assay. Clin Chem 53 (2007) 310-317
18. Jarvik G.P., Rozek L.S., Brophy V.H., et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 20 (2000) 2441-2447
19. Richter R.J., and Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9 (1999) 745-753
20. Krisch K. Enzymatic hydrolysis of diethyl-p-nitrophenylphosphate (E600) by human serum. Z Clin Chem 6 (1968) 41-45
21. Marton A., and Kalow W. Studies on aromatic esterase and cholinesterase of human serum. Can J Biochem Physiol 37 (1959) 1367-1373
22. Charlton-Menys V., Liu Y., and Durrington P.N. Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate. Clin Chem 52 (2006) 453-457
23. Richter R., Jampsa R., Jarvik G., Costa L.G., and Furlong C.E. Determination of Paraoxonase 1 (PON1) status and genotypes at specific polymorphic sites. In: Maines M.D., Costa L.G., Reed D.J., and Hodgson E. (Eds). Current Protocols in Toxicology (2004), John Wiley and Sons, NY, NY 4.12.11-14.12.19
24. Furlong C.E., Holland N., Richter R.J., Bradman A., Ho A., and Eskenazi B. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet Genomics 16 (2006) 183-190
25. Cole T.B., Jampsa R.L., Walter B.J., et al. Expression of human paraoxonase (PON1) during development. Pharmacogenetics 13 (2003) 357-364
26. Vineis P., and Perera F. Molecular epidemiology and biomarkers in etiologic cancer research: the new in light of the old. Cancer Epidemiol Biomarkers Prev 16 (2007) 1954-1965
27. Rundle A.G., Vineis P., and Ahsan H. Design options for molecular epidemiology research within cohort studies. Cancer Epidemiol Biomarkers Prev 14 (2005) 1899-1907
28. Nakanishi M., Takanami Y., Maruyama T., et al. The ratio of serum paraoxonase/arylesterase activity using an improved assay for arylesterase activity to discriminate PON1(R192) from PON1(Q192). J Atheroscler Thromb 10 (2003) 337-342
29. Brackley M., Carro-Ciampi G., Stewart D.J., Lowden J.A., Ray A.K., and Kalow W. Stability of the paraoxonase phenotyping ratio in collections of human sera with differing storage times. Res Commun Chem Pathol Pharmacol 41 (1983) 65-78
30. Holland N., Harmatz P., Golden D., et al. Cytogenetic damage in blood lymphocytes and exfoliated epithelial cells of children with inflammatory bowel disease. Pediatr Res 61 (2007) 209-214
31. Heyman M.B., Kirschner B.S., Gold B.D., et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 146 (2005) 35-40
32. Eskenazi B.B.A., Gladstone E.A., Jaramillo S., Birch K., and Holland N.T. CHAMACOS, a longitudinal birth cohort study: lessons from the fields. J Childrens Healt 1 (2003) 3-27
33. ISBER. Best practices for repositories: collection, storage, retrieval and distribution of biological materials for research. Cell Preservat Technol 6 (2008) 3-58
34. Connelly P.W., Maguire G.F., Picardo C.M., Teiber J.F., and Draganov D. Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. J Lipid Res 49 (2008) 245-250
35. Kujiraoka T., Oka T., Ishihara M., et al. A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J Lipid Res 41 (2000) 1358-1363
36. Holland N., Furlong C., Bastaki M., et al. Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns. Environ Health Perspect 114 (2006) 985-991
37. Stenzel J., Worek F., and Eyer P. Preparation and characterization of dialkylphosphoryl-obidoxime conjugates, potent anticholinesterase derivatives that are quickly hydrolyzed by human paraoxonase (PON1192Q). Biochem Pharmacol 74 (2007) 1390-1400
38. Khersonsky O., and Tawfik D.S. The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J Biol Chem 281 (2006) 7649-7656
39. van Himbergen T.M., van Tits L.J., Roest M., and Stalenhoef A.F. The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth J Med 64 (2006) 34-38
40. James R.W. A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med 44 (2006) 1052-1059
41. Marchegiani F., Marra M., Olivieri F., et al. Paraoxonase 1: genetics and activities during aging. Rejuvenation Res 11 (2008) 113-127